Your browser doesn't support javascript.
loading
Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer.
Hu, Congxue; Mi, Wanqi; Li, Feng; Zhu, Lun; Ou, Qi; Li, Maohao; Li, Tengyue; Ma, Yuheng; Zhang, Yunpeng; Xu, Yingqi.
Afiliação
  • Hu C; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
  • Mi W; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
  • Li F; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
  • Zhu L; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
  • Ou Q; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
  • Li M; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
  • Li T; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
  • Ma Y; Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010100, China.
  • Zhang Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
  • Xu Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. xuyingqi1987@163.com.
Sci Data ; 11(1): 74, 2024 Jan 16.
Article em En | MEDLINE | ID: mdl-38228620
ABSTRACT
Combination therapy can greatly improve the efficacy of cancer treatment, so identifying the most effective drug combination and interaction can accelerate the development of combination therapy. Here we developed a computational network biological approach to identify the effective drug which inhibition risk pathway crosstalk of cancer, and then filtrated and optimized the drug combination for cancer treatment. We integrated high-throughput data concerning pan-cancer and drugs to construct miRNA-mediated crosstalk networks among cancer pathways and further construct networks for therapeutic drug. Screening by drug combination method, we obtained 687 optimized drug combinations of 83 first-line anticancer drugs in pan-cancer. Next, we analyzed drug combination mechanism, and confirmed that the targets of cancer-specific crosstalk network in drug combination were closely related to cancer prognosis by survival analysis. Finally, we save all the results to a webpage for query ( http//bio-bigdata.hrbmu.edu.cn/oDrugCP/ ). In conclusion, our study provided an effective method for screening precise drug combinations for various cancer treatments, which may have important scientific significance and clinical application value for tumor treatment.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2024 Tipo de documento: Article